Literature DB >> 19185286

Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects.

Matthew J Girgenti1, Joshua Hunsberger, Catharine H Duman, Monica Sathyanesan, Rose Terwilliger, Samuel S Newton.   

Abstract

BACKGROUND: The neuroprotective and trophic actions of erythropoietin (EPO) have been tested in several animal models of insult, injury, and neurodegeneration. Recent studies in human volunteers demonstrated that EPO improves cognition and also elicits antidepressant effects. It is believed that the behavioral effects are mediated by EPO's trophic effect on neuronal systems. We therefore tested whether EPO is able to alter behavior and brain gene expression in rats.
METHODS: The expression of EPO and EPO receptor (EPOR) in multiple brain regions was examined by quantitative polymerase chain reaction, in situ hybridization, and immunohistochemistry. The regulation of EPO and the transcription factor hypoxia-induced factor-alpha (HIF1alpha) after electroconvulsive seizure (ECS) was investigated. Behavioral effects of EPO were tested in the rodent forced swimming and novelty-induced hypophagia (NIH) models. EPO gene profiles were obtained by microarray analysis of the hippocampus after intracerebroventricular infusion.
RESULTS: EPO and EPOR were widely expressed in the brain albeit at low levels. Highest level of EPO and EPOR were in the choroid plexus and striatum, respectively. Peripheral administration of EPO was sufficient to produce a robust antidepressant-like effect in the forced swim and NIH tests. Gene expression profiles revealed that EPO induces the expression of neurotrophic genes such as brain-derived neurotrophic factor, VGF (nonacronymic), and neuritin.
CONCLUSIONS: EPO is induced by ECS and independently exhibits antidepressant-like efficacy in the forced swim and NIH tests. EPO regulates the expression of genes implicated in antidepressant action and appears to be a candidate molecule for further testing in neuropsychiatry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185286     DOI: 10.1016/j.biopsych.2008.12.005

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  29 in total

Review 1.  Unexpected benefits of intermittent hypoxia: enhanced respiratory and nonrespiratory motor function.

Authors:  E A Dale; F Ben Mabrouk; G S Mitchell
Journal:  Physiology (Bethesda)       Date:  2014-01

2.  Neurotrophic paths in the treatment of depression.

Authors:  Shawn Hayley; Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

Review 3.  Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

4.  Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain.

Authors:  Annette Burkhart; Thomas Lars Andresen; Achim Aigner; Louiza Bohn Thomsen; Torben Moos
Journal:  Cell Mol Life Sci       Date:  2017-03-14       Impact factor: 9.261

5.  Carbamoylated erythropoietin produces antidepressant-like effects in male and female mice.

Authors:  Dayalan Sampath; Joshua McWhirt; Monica Sathyanesan; Samuel S Newton
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-08-24       Impact factor: 5.067

Review 6.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

7.  Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Ellen M Christensen; Jens D Bukh; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing
Journal:  Neuropsychopharmacology       Date:  2013-12-10       Impact factor: 7.853

8.  Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Gitte M Knudsen; Julian Macoveanu; Allan R Hansen; Olaf B Paulson; Hartwig R Siebner; Lars V Kessing
Journal:  Trials       Date:  2010-10-13       Impact factor: 2.279

Review 9.  Vascular growth factors in neuropsychiatry.

Authors:  Samuel S Newton; Neil M Fournier; Ronald S Duman
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

Review 10.  Erythropoietin for infants with hypoxic-ischemic encephalopathy.

Authors:  Ronald J McPherson; Sandra E Juul
Journal:  Curr Opin Pediatr       Date:  2010-04       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.